Virtual biotech company puts thousands of AI scientist agents to work on drug discovery
Researchers at Stanford Medicine have launched a virtual biotech company powered by 37,000 AI agents. These agents simulate an entire organizational structure to manage the drug discovery pipeline, from target identification to clinical trial design.
Why it matters
This represents a significant shift in pharmaceutical R&D, potentially reducing the time and cost of drug development by automating complex research workflows.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Credit: Yuri Shkoda from Pexels The latest company to spin out of a Stanford Medicine lab is a biotech undertaking with 37,000 employees—and none of them are human. There's no lab space, no lunch breaks and no payroll. It's an artificial intelligence-powered virtual biotech company that's the brainchild of associate professor of biomedical data science James Zou, Ph.D., who is also the principal investigator of a virtual lab that launched in 2025, and graduate student Harrison Zhang.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in